文献速递药物不良反应与药物警戒特殊人群用药

艾曲泊帕在不同年龄组中的安全性:真实世界药物警戒与随机临床试验分析

Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials.
PubMed 文献 · Clin Pharmacol Ther · 2023-05-08

该研究利用VigiBase和FAERS数据库2008至2022年的个例安全报告,结合截至2022年7月28日的随机临床试验meta分析,按年龄组(0-17岁、18-64岁、≥65岁)对艾曲泊帕相关不良事件进行不成比例分析。结果显示肝胆疾病、血栓、皮肤及皮下组织疾病、感染等在不同年龄组存在差异;meta分析显示成人ITP与儿童ITP在四个系统器官分类上存在差异。所有年龄组均观察到丙氨酸氨基转移酶、天冬氨酸氨基转移酶和血胆红素升高的信号。

要点

  • 所有年龄组均观察到肝酶和胆红素升高信号
  • 儿童ITP中尿路感染和背痛显示信号
  • 成人与儿童ITP在感染等四个系统器官分类上存在差异

核心结论

  • 艾曲泊帕相关不良事件在不同年龄组呈现差异,肝胆指标升高信号见于所有年龄组。

研究设计与样本

  • 基于VigiBase和FAERS数据库2008至2022年个例安全报告的不成比例分析,按0-17岁、18-64岁、≥65岁分组。
  • 结合截至2022年7月28日随机临床试验的meta分析。

主要发现

  • 肝胆疾病、血栓、皮肤及皮下组织疾病、感染等不良事件在各年龄组观察到的差异不同。
  • meta分析显示成人ITP与儿童ITP在感染和侵染、全身性疾病及给药部位情况、皮肤及皮下组织疾病、检查这四个系统器官分类存在差异。
  • 所有年龄组均观察到丙氨酸氨基转移酶、天冬氨酸氨基转移酶和血胆红素升高的信号。
  • 儿童中尿路感染和背痛显示信号。

临床怎么用

  • 临床使用艾曲泊帕时应关注不同年龄组的不良事件谱,尤其所有年龄组的肝胆指标变化。
  • 对儿童患者需留意尿路感染和背痛等信号。

局限性

  • 药物警戒研究存在固有局限性,需更多试验评估不同年龄的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eltrombopag is clinically approved for use in immune thrombocytopenia (ITP), chronic hepatitis C-related thrombocytopenia, and aplastic anemia and suitable for children; however, data on its overall safety profile are scarce. This study aimed to explore the clinical features of adverse drug events (ADEs) associated with eltrombopag in different age groups using individual case safety reports (ICSRs) from the World Health Organization database VigiBase and the US Food and Drug Administration Adverse Event Reporting System database from 2008 to 2022 in combination with a meta-analysis of data from randomized clinical trials in the literature from inception to July 28, 2022. We conducted disproportionality analyses by grouping patients into the following age groups: 0-17 (0-23 months, 2-11 years, and 12-17 years), 18-64, and ≥ 65 years. The ADEs about hepatobiliary disorders, thrombosis, skin and subcutaneous tissue disorders, infections, and so on were observed more differently in each age group. Meta-analysis results showed differences in the four system organ classes between adults and children with ITP: infections and infestations, general disorders and administration site conditions, skin and subcutaneous tissue disorders, and investigations. The adverse drug reactions in the latest version of instructions were searched in the databases to analyze their postmarketing safety signal strength. We observed signals of elevated alanine aminotransferase, aspartate aminotransferase, and blood bilirubin levels in all age groups. For children, urinary tract infection and back pain showed signals. Due to the inherent limitations of pharmacovigilance studies, more experiments are needed to assess the risks of eltrombopag in different ages.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Qu H, Wu J, Ma C, et al. Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials. Clin Pharmacol Ther. 2023. PMID: 37087633. doi:10.1002/cpt.2918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。